Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids.

Realini N, Rubino T, Parolaro D.

Pharmacol Res. 2009 Aug;60(2):132-8. doi: 10.1016/j.phrs.2009.03.006. Epub 2009 Mar 17. Review.

PMID:
19559364
2.

Redox dysregulation, neurodevelopment, and schizophrenia.

Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M.

Curr Opin Neurobiol. 2009 Apr;19(2):220-30. doi: 10.1016/j.conb.2009.05.001. Epub 2009 May 27. Review.

PMID:
19481443
3.

Wiring and firing neuronal networks: endocannabinoids take center stage.

Harkany T, Mackie K, Doherty P.

Curr Opin Neurobiol. 2008 Jun;18(3):338-45. doi: 10.1016/j.conb.2008.08.007. Review.

4.

Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects.

Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, Devi LA, Hurd YL.

Eur Neuropsychopharmacol. 2008 Nov;18(11):826-34. doi: 10.1016/j.euroneuro.2008.06.009.

5.

Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning.

Mulder J, Aguado T, Keimpema E, Barabás K, Ballester Rosado CJ, Nguyen L, Monory K, Marsicano G, Di Marzo V, Hurd YL, Guillemot F, Mackie K, Lutz B, Guzmán M, Lu HC, Galve-Roperh I, Harkany T.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8760-5. doi: 10.1073/pnas.0803545105. Epub 2008 Jun 18.

6.

Presynaptic modulation by endocannabinoids.

Lovinger DM.

Handb Exp Pharmacol. 2008;(184):435-77. Review.

PMID:
18064422
7.

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G.

Lancet. 2007 Jul 28;370(9584):319-28. Review.

PMID:
17662880
8.

Hardwiring the brain: endocannabinoids shape neuronal connectivity.

Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urbán GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T.

Science. 2007 May 25;316(5828):1212-6.

9.

Neurodevelopmental changes in working memory and cognitive control.

Bunge SA, Wright SB.

Curr Opin Neurobiol. 2007 Apr;17(2):243-50. Epub 2007 Feb 23. Review.

PMID:
17321127
10.

The emerging functions of endocannabinoid signaling during CNS development.

Harkany T, Guzmán M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K.

Trends Pharmacol Sci. 2007 Feb;28(2):83-92. Epub 2007 Jan 10. Review.

PMID:
17222464
11.

Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons.

Fortin DA, Levine ES.

Cereb Cortex. 2007 Jan;17(1):163-74. Epub 2006 Feb 8.

PMID:
16467564
12.
13.

Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types.

Bodor AL, Katona I, Nyíri G, Mackie K, Ledent C, Hájos N, Freund TF.

J Neurosci. 2005 Jul 20;25(29):6845-56.

14.

Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia.

Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G, Stuart GW, Yung A, Phillips L, McGorry PD.

Schizophr Bull. 2005 Jul;31(3):672-96. Epub 2005 Jul 14. Review.

PMID:
16020551
15.

The environment and schizophrenia: the role of cannabis use.

Henquet C, Murray R, Linszen D, van Os J.

Schizophr Bull. 2005 Jul;31(3):608-12. Epub 2005 Jun 23.

PMID:
15976013
16.

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.

Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW.

Biol Psychiatry. 2005 May 15;57(10):1117-27.

PMID:
15866551
17.

Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000-2001.

O'Brien MS, Anthony JC.

Neuropsychopharmacology. 2005 May;30(5):1006-18. Erratum in: Neuropsychopharmacology. 2005 Aug;30(8):1588.

18.

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH.

Biol Psychiatry. 2005 Mar 15;57(6):594-608.

PMID:
15780846
19.

Maturation of cognitive processes from late childhood to adulthood.

Luna B, Garver KE, Urban TA, Lazar NA, Sweeney JA.

Child Dev. 2004 Sep-Oct;75(5):1357-72.

PMID:
15369519
20.

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Harrison PJ, Weinberger DR.

Mol Psychiatry. 2005 Jan;10(1):40-68; image 5. Review. Erratum in: Mol Psychiatry. 2005 Aug;10(8):804. Mol Psychiatry. 2005 Apr;10(4):420.

PMID:
15263907

Supplemental Content

Support Center